Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia

Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia. We evaluated the function of Meningioma 1 (MN1), a co-factor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of MN1. MN1 was required for in vivo leukemogenicity of MLL positive murine and human leukemia cells. Loss of MN1 inhibited cell cycle and proliferation, promoted apoptosis and induced differentiation of MLL-rearranged cells. Expression analysis and chromatin immunoprecipitation with sequencing from previously reported data sets demonstrated that MN1 primarily maintains active transcription of HOXA9 and HOXA10, which are critical downstream genes of MLL, and their target genes like BCL2, MCL1 and Survivin. Treatment of MLL-rearranged primary leukemia cells with anti-MN1 siRNA significantly reduced their clonogenic potential in contrast to normal CD34+ hematopoietic progenitor cells, suggesting a therapeutic window for MN1 targeting. In summary, our findings demonstrate that MN1 plays an essential role in MLL fusion leukemias and serve as a therapeutic target in MLL-rearranged acute myeloid leukemia.

[1]  D. Heckl,et al.  CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo , 2017, Haematologica.

[2]  M. Heuser,et al.  RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo , 2017, Leukemia.

[3]  E. Clappier,et al.  The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.

[4]  Thomas A Milne,et al.  Mouse models of MLL leukemia: recapitulating the human disease. , 2017, Blood.

[5]  E. Brown,et al.  Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. , 2016, Current cancer drug targets.

[6]  D. Plas,et al.  S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. , 2016, The Journal of clinical investigation.

[7]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[8]  Scott A. Armstrong,et al.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. , 2016, The Journal of clinical investigation.

[9]  S. Armstrong,et al.  MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. , 2016, The Journal of clinical investigation.

[10]  R. Slany.  The molecular mechanics of mixed lineage leukemia , 2016, Oncogene.

[11]  J. L. Mateo,et al.  CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool , 2015, PloS one.

[12]  S. Armstrong,et al.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.

[13]  M. Nóbrega,et al.  PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway , 2014, Leukemia.

[14]  M. Heuser,et al.  Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling , 2014, Leukemia.

[15]  Michael Rothe,et al.  Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.

[16]  Toru Okamoto,et al.  HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia , 2013, Oncotarget.

[17]  S. Lowe,et al.  An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. , 2012, Blood.

[18]  A. Kohlmann,et al.  Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia , 2012, Genes, chromosomes & cancer.

[19]  A. Hero,et al.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells. , 2012, Blood.

[20]  J. Hess,et al.  CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. , 2011, Cancer cell.

[21]  M. Caligiuri,et al.  Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. , 2011, Blood.

[22]  Nicola K. Wilson,et al.  Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. , 2011, Cancer cell.

[23]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[24]  Yi Zhang,et al.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[25]  P. Aplan,et al.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. , 2010, Blood.

[26]  J. Schwaller,et al.  Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia , 2010, Leukemia.

[27]  M. Heuser,et al.  Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. , 2009, Blood.

[28]  C. Bach,et al.  Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia , 2009, PLoS biology.

[29]  W. Hiddemann,et al.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Caligiuri,et al.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Ono,et al.  AML1 mutations induced MDS and MDS/AML in a mouse BMT model. , 2008, Blood.

[32]  R. Humphries,et al.  Hox genes in hematopoiesis and leukemogenesis , 2007, Oncogene.

[33]  A. Schambach,et al.  MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. , 2007, Blood.

[34]  E. Zwarthoff,et al.  The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription , 2007, Oncogene.

[35]  S. Shurtleff,et al.  MN1 overexpression is an important step in the development of inv(16) AML , 2007, Leukemia.

[36]  Ying-Wei Lin,et al.  Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. , 2007, Cancer research.

[37]  K. Döhner,et al.  High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. , 2006, Blood.

[38]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[39]  M. D. Boer,et al.  The MLL recombinome of acute leukemias , 2006, Leukemia.

[40]  P. Riegman,et al.  Targeted Disruption of the Mn1 Oncogene Results in Severe Defects in Development of Membranous Bones of the Cranial Skeleton , 2005, Molecular and Cellular Biology.

[41]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[42]  E. Zwarthoff,et al.  The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription , 2003, Oncogene.